3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
Azacitidine
41
Cytarabine
27
fludarabine phosphate
25
Cyclophosphamide
23
venetoclax
21
fludarabine
21
Peripheral Blood Stem Cell Transplantation
20
Mycophenolic Acid
17
Filgrastim
17
Decitabine
17
Tacrolimus
16
Whole-Body Irradiation
15
ruxolitinib
14
Cyclosporine
14
Busulfan
14
Melphalan
12
Methotrexate
10
Imatinib Mesylate
10
Stem Cell Transplantation
9
Antilymphocyte Serum
8
Alemtuzumab
8
nilotinib
7
decitabine and cedazuridine drug combination
7
Granulocyte Colony-Stimulating Factor
7
Rituximab
6
Injections
6
Idarubicin
6
Dasatinib
6
Clofarabine
6
AP 1903 reagent
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Clinical Laboratory Techniques
×
Myeloid
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled